CenterBook Partners LP Invests $2.38 Million in GH Research PLC $GHRS

CenterBook Partners LP purchased a new stake in GH Research PLC (NASDAQ:GHRS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 166,153 shares of the company’s stock, valued at approximately $2,376,000. CenterBook Partners LP owned approximately 0.32% of GH Research as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. AdvisorShares Investments LLC lifted its stake in GH Research by 15.0% in the second quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company’s stock valued at $466,000 after acquiring an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of GH Research in the 2nd quarter valued at $79,000. Virtus Investment Advisers LLC acquired a new stake in shares of GH Research in the 2nd quarter valued at $89,000. Stempoint Capital LP bought a new stake in GH Research in the second quarter worth $1,229,000. Finally, HighVista Strategies LLC bought a new stake in GH Research in the second quarter worth $637,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

Analysts Set New Price Targets

GHRS has been the topic of several recent research reports. Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Citigroup reiterated a “market outperform” rating on shares of GH Research in a report on Tuesday, January 6th. Finally, Guggenheim reissued a “buy” rating and issued a $29.00 price target on shares of GH Research in a research report on Monday, January 5th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.11.

GH Research Price Performance

NASDAQ:GHRS opened at $15.80 on Friday. GH Research PLC has a one year low of $7.98 and a one year high of $19.51. The company has a fifty day moving average price of $14.85 and a 200 day moving average price of $14.01. The stock has a market cap of $822.07 million, a P/E ratio of -21.35 and a beta of 0.99.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.